期刊文献+

硫氧还蛋白相互作用蛋白与肥胖相关性肾小球病的研究进展

Progress in the research of thioredoxin-interacting proteins and obesity-related glomerulopathy
下载PDF
导出
摘要 随着全球肥胖患病率逐渐增加,肥胖相关性肾小球病(ORG)的发病率日益增高。ORG以非肾病性蛋白尿为主要临床表现,随病情发展可进展至终末期肾病。病理表现以肾小球肥大、局灶节段肾小球硬化为特征。研究表明,ORG的发病与慢性组织低度炎症反应、氧化应激、肾素-血管紧张素-醛固酮系统激活及胰岛素抵抗等密切相关。硫氧还蛋白相互作用蛋白(Txnip)为一种多蛋白复合物,可促进氧化应激,参与多种炎症反应。本文将对Txnip与肥胖相关性肾小球病的研究进展进行综述。 The incidence of obesity-related glomerular nephropathy(ORG)is increasing,along with the increasing prevalence of obesity worldwide.Non-nephrotic proteinuria is the main clinical manifestation of ORG;ORG eventually progresses to end-stage renal disease.The pathological manifestations are characterized by glomerular hypertrophy or focal segmental glomerular sclerosis.Researchers have shown that the incidence of ORG is closely related to chronic inflammatory responses,oxidative stress,the activation of the renin-angiotensinaldosterone system,and insulin resistance.Thioredoxin-interacting protein(Txnip)is a major component of a multiprotein complex that promotes oxidative stress and plays an important role in a variety of inflammatory processes.This article will review the research progresses on Txnip and obesity-related glomerulopathy.
作者 刘佳琳 姜红 姜红堃 LIU Jialin;JIANG Hong;JIANG Hongkun(Department of Pediatrics,The First Hospital,China Medical University,Shenyang 110001,China)
出处 《中国医科大学学报》 CAS CSCD 北大核心 2020年第12期1130-1132,1142,共4页 Journal of China Medical University
基金 国家自然科学基金(81300130) 辽宁省省直医院改革重点临床科室诊疗能力建设项目(LNCCC-D06-2015) 辽宁省高等学校基本科研项目(LFWK201701)。
关键词 肥胖相关性肾小球病 硫氧还蛋白相互作用蛋白 氧化应激 obesity-related glomerulopathy thioredoxin-interacting protein oxidative stress
  • 相关文献

参考文献4

二级参考文献59

  • 1WeisingerJR, KempsonRL, EldridgeFL, et al.The nephritic syndrome:a complication of massive obesity[J].Ann Intern Med, 1974, 81(4):440-447.
  • 2NolanE, O'MearaYM, GodsonC.Lipid mediators of inflammation in obesity-related glomerulopathy[J].Nephrol Dial Transplant, 2013, 28 (4):22-29.
  • 3de VriesAP, RuggenentiP, RuanXZ.Fatty kidney:emerging role of ectopic lipid in obesity-related renal disease[J].Lancet Diabetes Endocrinol, 2014, 2(5):417-426.
  • 4SnyderS, TurnerGA, TurnerA.Obesity-related kidney disease[J].Prim Care, 2014, 41(4):875-893.
  • 5SatirapojB, SupasyndhO, MayteedolN, et al.Obesity and its relation to chronic kidney disease:population-based, cross-sectional study of a Thai armypopulation and relatives[J].Nephrology (Carlton), 2013, 18(3):229-234.
  • 6TsuboiN, KoikeK, HiranoK, et al.Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy[J].Clin Exp Nephrol, 2013, 17(3):379-385.
  • 7HenHM, LiuZH.Podocyte lesions in patients with obesity-related glomerulopathy[J].Am J Kidney Dis, 2006, 48(5):772-779.
  • 8YadavH, QuijanoC, KamarajuAK, et al.Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling[J].Cell Metab, 2011, 14(1):67-79.
  • 9PorrecaE, Di FebboC, VitacolonnaE, et al.Transforming growth factor-β1 levels in hypertensive patients:association with body mass index and leptin[J].Am J Hypertens, 2002, 15(9):759-765.
  • 10WangX, ChenH, ZhangM, et al.Roles of mast cells and monocyte chemoattractant protein-1 in the renal injury of obesity-related glomerulopathy[J].Am J Med Sci, 2013, 346(4):295-301.

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部